EMEA-001811-PIP04-21
Table of contents
Key facts
| Active substance |
ligelizumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0355/2021
|
| PIP number |
EMEA-001811-PIP04-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic inducible urticaria
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|